Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer

BACKGROUND: The prognosis of gastric cancer continues to remain poor, and epigenetic drugs like histone deacetylase inhibitors (HDACi) have been envisaged as potential therapeutic agents. Nevertheless, clinical trials are facing issues with toxicity and efficacy against solid tumors, which may be pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Amnekar, Ramchandra Vigay, Khan, Shafqat Ali, Rashid, Mudasir, Khade, Bharat, Thorat, Rahul, Gera, Poonam, Shrikhande, Shailesh V, Smoot, Duane T, Ashktorab, Hassan, Gupta, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Basic Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029347/
https://www.ncbi.nlm.nih.gov/pubmed/32103870
http://dx.doi.org/10.3748/wjg.v26.i6.598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029347/
https://www.ncbi.nlm.nih.gov/pubmed/32103870
http://dx.doi.org/10.3748/wjg.v26.i6.598

Ejemplares similares